ROCKY ROAD AHEAD FOR NEW FDA CHIEF CALIFF
Applied Clinical Trials
; 31(3):6, 2022.
Artículo
en Inglés
| ProQuest Central | ID: covidwho-20244570
ABSTRACT
Final Senate approval by a historically narrow 50-46 vote came only after the White House and Califf's supporters lobbied hard to gain sufficient support, a success that is very different from Califf's 89-4 approval back in 2016. Pressure to help control the high cost of prescription drugs will continue to drive FDA support for developing complex generic drugs and biosimilars. There is pressure to clarify rules governing e-cigarettes;a need to address serious health problems arising from contaminated food and seafood, including significant volumes of imported products;and the safety of cosmetic products, dietary supplements, sunscreens, and other non-prescription products raise additional complex issues.
Buscar en Google
Colección:
Bases de datos de organismos internacionales
Base de datos:
ProQuest Central
Tópicos:
Medicina tradicional
Idioma:
Inglés
Revista:
Applied Clinical Trials
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS